Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

FROM MYOCARDIAL FIBROSIS TO CONGESTIVE HEART FAILURE

Congestive cardiac failure has become one of the major health challenges of the 21st century and new therapies are needed to address this problem. The concentration of vasoactive intestinal peptide (VIP) in the heart has been shown to decrease as fibrosis (the pathology leading to heart failure) increases and to become undetectable in end stage cardiomyopathy. We sought to determine whether replenishment of myocardial VIP might treat myocardial fibrosis and therefore represent a new therapeutic target.

https://pubmed.ncbi.nlm.nih.gov/31449808/

Cardiovascular Drugs Market Size is Projected to Reach USD 63.96 Billion at CAGR to 3.8% by 2026.

https://finance.yahoo.com/news/cardiovascular-drugs-market-size-projected-053000512.html